

Date 12/12/2025
Your Ref
Our Ref 10849

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – PRESCRIBING

I write in response to your request for information in relation to prescribing.

Question:

- How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	343
1.2 Apalutamide (Erleada)	5<
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	8
1.4 Darolutamide (Nubeqa)	19
1.5 Enzalutamide (Xtandi)	199
1.6 Talazoparib (Talzenna)	0
1.7 Docetaxel	85
1.8 Relugolix (Orgovyx, Ryeqo)	0
1.9 Olaparib (Lynparza)	25

Question:

- How many patients were treated with these products specifically for **prostate cancer** (ICD-10 code = C61) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	30
2.2 Olaparib (Lynparza) for prostate cancer	0
2.3 Talazoparib (Talzenna) for prostate cancer	0
2.4 Relugolix (Orgovyx) for prostate cancer	0

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
Lothian NHS Board is the common
name of Lothian Health Board

Question:

3. How many patients received their **first cycle** or **first dose** of the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated in Cycle 1 or Dose 1
3.1 Abiraterone (Zytiga or generic abiraterone)	49
3.2 Apalutamide (Erleada)	0
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	5<
3.4 Darolutamide (Nubeqa)	6
3.5 Enzalutamide (Xtandi)	37

Question:

4. How many patients were treated with the following combinations in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Please give **total** number of patients and number of patients receiving their **first dose** or **first cycle**.

Answer:

Name of medicine	Total Number patients treated	Number patients received cycle 1 or dose 1
4.1 Darolutamide (Nubeqa) + Docetaxel	5<	5<
4.2 Darolutamide (Nubeqa)	14	5<
4.3 Olaparib (Lynparza) + Abiraterone	25	7

Question:

5. How many patients received the following products for **non-metastatic hormone sensitive prostate cancer** in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
5.1 Abiraterone	43
5.2 Enzalutamide	49

Question:

6. How many patients with high grade epithelial stage III or IV **ovarian, fallopian tube or primary peritoneal cancer** were treated with **platinum chemotherapy** between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available?

7. How many patients with high grade epithelial stage III or IV **ovarian, fallopian tube or primary peritoneal cancer** received **maintenance therapy** between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available?

Answer:

Available data is not to the level of granularity to be able to report by stage. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

Question:

8. How many patients were treated with **olaparib (Lynparza)** for the following types of cancer between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available?

Answer:

Type of cancer	ICD-10 codes	No. of patients
Breast Cancer	C50* or D05	<5
Ovarian Cancer	C56* or C57* or C79.6 or C79.8 or C48.1 or C48.2	20
Prostate Cancer	C61*	0

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

9. How many patients were treated with olaparib (Lynparza) for the following indications and BlueTeq CDF codes between 1st Jul 2025 and 30th Sep 2025, or latest 3-month period for which data is available?

Answer:

Available data is not at a level of granularity to be able to answer this question. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

BlueTeq CDF code	BlueTeq CDF description (copied from CDF List)	Number of patients
OLAP1a or OLAPb	Maintenance treatment in patients with high grade epithelial stage III or IV <u>ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy</u> AND have a deleterious or suspected deleterious germline and/or somatic BRCA mutation	Not available
OLAP 2	Maintenance treatment in patients with high grade epithelial <u>ovarian, fallopian tube or primary peritoneal carcinoma</u> who HAVE a deleterious or suspected deleterious germline and/or somatic BRCA mutation and a recent FIRST RELAPSE of platinum-sensitive disease and are now <u>in response following a SECOND platinum- based chemotherapy</u>	Not available
OLAP 3	Maintenance treatment in patients with high grade epithelial <u>ovarian, fallopian tube or primary peritoneal carcinoma</u> who have a deleterious or suspected deleterious germline and/or somatic BRCA mutation and a recent SECOND OR SUBSEQUENT relapse of platinum-sensitive disease and are now <u>in response following a THIRD OR SUBSEQUENT platinum-based chemotherapy</u>	Not available
OLAP 4	Maintenance treatment in patients with high grade epithelial stage III or IV <u>ovarian, fallopian tube or primary peritoneal carcinoma</u> who are in response following platinum-based FIRST line chemotherapy AND whose cancer has a positive status for homologous recombination deficiency as defined by the presence of either a deleterious or suspected deleterious BRCA 1/2 germline and/or somatic mutation or genomic instability	Not available
OLAP 5	Olaparib monotherapy as <u>adjuvant</u> treatment of high-risk <u>TRIPLE NEGATIVE early breast cancer</u> treated with neoadjuvant or adjuvant chemotherapy and definitive local therapy in patients with a deleterious or suspected deleterious germline BRCA mutation	Not available
OLAP 6	<u>Adjuvant</u> treatment of high-risk <u>HORMONE RECEPTOR POSITIVE HER 2 NEGATIVE early breast cancer</u> treated with neoadjuvant or adjuvant chemotherapy and definitive local therapy in patients with a deleterious or suspected deleterious germline BRCA mutation	Not available
OLAP 7	Olaparib monotherapy for <u>metastatic castration-</u>	Not

	<u>resistant prostate cancer</u> bearing germline and/or somatic <u>BRCA 1 or 2 mutations</u> in patients who have progressed following previous treatment with an androgen receptor targeted agent AND HAVE ALSO BEEN TREATED WITH DOCETAXEL	available
OLAP 8	Olaparib monotherapy for <u>metastatic castration-resistant prostate cancer</u> bearing germline and/or somatic <u>BRCA 1 or 2 mutations</u> in patients who have progressed following previous treatment with an androgen receptor targeted agent AND HAVE NOT BEEN PREVIOUSLY TREATED WITH DOCETAXEL	Not available
OLAP 9	<u>Olaparib + abiraterone</u> for the treatment of <u>metastatic hormone- relapsed (castrate-resistant) prostate cancer</u> in patients who are treatment naïve to androgen receptor inhibitors and in whom chemotherapy is not yet clinically indicated or appropriate	Not available

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive